Monash IVF Group (MVF) H1 2025 earnings summary

Executive summary

• Achieved 11.6% revenue growth to $140.3m and 10.7% underlying EBITDA growth to $35.6m in 1H25, with underlying NPAT up 5.5% to $15.8m and reported NPAT at $17.3m, in line with guidance.

• All business segments—Domestic ARS, Women's Imaging/Ultrasound, and International—delivered robust revenue and earnings growth.

• Fully franked interim dividend increased to 2.6 cents per share.

• Market leading clinical pregnancy rates increased by 1.2% to 40.2%.

Financial highlights

• Revenue up 11.6% to $140.3m, with underlying EBITDA up 10.7% to $35.6m and EBITDA margin steady at 25%.

• Underlying NPAT rose 5.5% to $15.8m; reported NPAT up 34.4% to $17.3m.

• Reported EBITDA includes $4.1m net insurer settlement from NiPGT class action.

• Earnings per share increased to 4.4 cents from 3.3 cents year-over-year.

• Free cash flow was negative $6.5m, impacted by class action payments and capital expenditure.

Outlook and guidance

• FY25 underlying group NPAT expected between $30.0m and $31.0m, slightly above prior year.

• Short-term volatility in domestic ART sector expected to subside, with medium- to long-term growth supported by structural demand drivers such as genetics, donor, and egg freezing services.

• Non-regular FY25 items include new clinic commissioning, class action costs, and investment impairment.

• Volume growth for FY25 expected to be flat, with 2-3% market growth anticipated from FY26 onward.

• EBITDA margin improvement of 2% targeted by 2027, driven by cost optimization and technology investments.